The Asian Fund for Cancer Research is proud to support Arbele, our finalist of the 2020 BRACE Award Competition, to present at the Virtual 2021 China BioMed Forum during the 39th J.P. Morgan Healthcare Conference. This Virtual Event will take place on January 12-13, 2021, co-hosted by our partner organization, China Pharmaceutical Innovation and Research Development Association (PhIRDA).
Arbele is a biotech and biopharmaceutical company focused on inventing proprietary immunotherapeutic platforms to accelerate the development of antibody-based biologics to treat GI cancers and solid tumors. Arbele’s lead antibody, ARB202, binds to the CDH17 gene and the T-cell receptor antigen CD3, to effect cancer immunotherapy at tumors sites. Having completed the GMP manufacturing of drug product and GLP pre-clinical safety trials, ARB202 is an IND-ready asset, promising to be a “first-in-class” innovative medicine for clinical trials to treat GI cancer patients.
This Forum will focus on the new dynamics and trends of global investment and financing, select high-quality innovative companies to showcase their innovations and achievements, promote international cooperation in the field of pharmaceutical innovation and jointly build new pattern of the pharmaceutical industry in the post-pandemic era.
Register FOR FREE to attend: https://zhibo.m-events.cn/live/watch/general?id=o92y0v6m
